Blueprint Medicines Corp Aktie
Deine Einschätzung
Blueprint Medicines Corp Aktie
Was spricht für und gegen Blueprint Medicines Corp in den nächsten Jahren?
Pro
Kontra
Rendite von Blueprint Medicines Corp im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp | - | - | - | - | - | - | - |
| Ligand Pharmaceuticals | 1,55 % | 0,00 % | 18,07 % | 105,24 % | 18,07 % | 180,00 % | 61,38 % |
| United Therapeutics | 1,15 % | -0,65 % | -5,14 % | 82,53 % | 13,97 % | 133,01 % | 186,47 % |
| Ionis Pharmaceuticals Inc. | 0,22 % | 0,50 % | 0,73 % | 135,38 % | -6,21 % | 98,63 % | 78,89 % |
Kommentare
News
Spirits on the Rocks? The Battle for Jack Daniels
The global premium spirits sector is navigating a significant shift. After a period of high consumer demand driven by COVID-era stay-at-home trends, the market is now normalizing. This return to
Irresistible Change: How to Spot Real Growth
Phil Gilbert, serial entrepreneur and former general manager at IBM, joins this episode of Motley Fool Money to talk about his new book, Irresistible Change: A Blueprint for Earning Buy-In and
Offshore Titans: Transocean Buys Valaris for $5.8B
Transocean Ltd. (NYSE: RIG) has made the definitive move to cement its status as the undisputed leader in offshore drilling. By agreeing to acquire Valaris Limited (NYSE: VAL) in an all-stock





